PHRX (Pharmagen) Other Operating Expense: $-0.00 Mil (TTM As of Mar. 2014)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Pharmagen Other Operating Expense?

Pharmagen PHRX -90.00% Other Operating Expense is $-0.00 Mil as of Mar. 2014.

Pharmagen's Other Operating Expense for the three months ended in Mar. 2014 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2014 was $-0.00 Mil.

Pharmagen's quarterly Other Operating Expense stayed the same from Sep. 2013 ($0.00 Mil) to Dec. 2013 ($0.00 Mil) but then declined from Dec. 2013 ($0.00 Mil) to Mar. 2014 ($0.00 Mil).

Pharmagen's annual Other Operating Expense declined from Jun. 2011 ($0.00 Mil) to Dec. 2012 ($-0.00 Mil) but then increased from Dec. 2012 ($-0.00 Mil) to Dec. 2013 ($0.00 Mil).

Pharmagen Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Pharmagen's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmagen Other Operating Expense Chart

Pharmagen Annual Data
Trend Jun10 Jun11 Dec12 Dec13
Other Operating Expense
0.00 0.00 -0.00 0.00

Pharmagen Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 0.00

Pharmagen Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-0.00 Mil mean?
Pharmagen (PHRX) has a Other Operating Expense of $-0.00 Mil as of Mar. 2014. Other operating expenses that a company records on its income statement. View historical data on Pharmagen and its competitors.
Is Pharmagen's Other Operating Expense too high?
Pharmagen's current Other Operating Expense is $-0.00 Mil.
How does Pharmagen's Other Operating Expense compare to FZMD and SNYR?
Pharmagen's Other Operating Expense of $-0.00 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Distribution company?
A good Other Operating Expense depends on the Medical Distribution industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Pharmagen and its competitors. Pharmagen's current Other Operating Expense is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmagen stock overvalued right now?
Pharmagen (PHRX) has a current Other Operating Expense of $-0.00 Mil. The current Other Operating Expense is $-0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Pharmagen (PHRX), the current Other Operating Expense is $-0.00 Mil as of Mar. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmagen Business Description

Address 9337 Fraser Avenue, Silver Spring, MD, USA, 20910
Pharmagen Inc as a distributor of specialty drugs, compounding and admix pharmacy, and producer of over-the-counter branded multivitamins to the healthcare provider market. The company distributes hard-to-find and specialty drugs to the healthcare provider market throughout the United States, while functioning as an aggregator of real-time market demand for these products.